Akkermansia muciniphila vs Larazotide
Two gut-barrier approaches on completely different routes — a bacterium that rebuilds the mucin layer with a mixed but genuinely positive human RCT record, and a synthetic tight-junction regulator that failed its pivotal trial.
Short answer
Both have human clinical data behind them, which makes the goal the real difference between Akkermansia and larazotide. For a reader focused on gut barrier integrity, metabolic syndrome and insulin sensitivity, Akkermansia is the relevant choice; larazotide is marketed for leaky gut and celiac disease.
Akkermansia muciniphila
Pasteurized Akkermansia, Muc(T)
The founding human RCT was small (32 completers) and positive only for the pasteurized strain, not live bacteria; a larger 2026 follow-up in metabolic syndrome missed its primary endpoint while a separate 2026 maintenance trial confirmed a real effect — and live capsules, which is mostly what's sold as a 'probiotic,' have essentially no human trial data of their own.
Full Akkermansia muciniphila evidence reviewLarazotide
AT-1001
A tight-junction regulator with real celiac Phase 2 data — but its pivotal Phase 3 failed, and the supplement use runs far ahead of the evidence.
Full Larazotide evidence reviewAkkermansia muciniphila vs Larazotide: head to head
- FDA status / approved use
Akkermansia muciniphila
Sold as a dietary supplement with no FDA approval; pasteurized form authorized as an EU Novel FoodLarazotide
Investigational and not FDA-approved; pivotal Phase 3 trial halted in 2022- Marketed for
Akkermansia muciniphila
Gut barrier integrity, metabolic syndrome, insulin sensitivityLarazotide
Leaky gut, celiac disease- Outcome areas
Akkermansia muciniphila
Gut health; Blood sugar / insulin sensitivityLarazotide
Gut health- Evidence grade
Akkermansia muciniphila
Clinical dataLarazotide
Clinical data- How it works
Akkermansia muciniphila
Mucus-dwelling gut bacterium; a heat-stable surface protein improves the gut barrierLarazotide
Zonulin antagonist designed to tighten the junctions between intestinal cells- Route and dosing
Akkermansia muciniphila
Oral capsule, taken dailyLarazotide
Oral capsule swallowed before meals- Headline human result
Akkermansia muciniphila
Regained 1.2 kg vs 3.2 kg on placebo after dieting in a 90-person 2026 RCT; a 142-person 2026 trial missed its primary endpointLarazotide
Phase 3 CeDLara trial stopped in 2022 after interim analysis showed it would miss its symptom endpoint- Strongest evidence
Akkermansia muciniphila
Depommier 2019 proof-of-concept RCT, Nat MedAkkermansia muciniphila evidence reviewPubMed 31263284Larazotide
Leffler, Gastroenterology 2015Larazotide evidence reviewPubMed 25683116- Key safety signal
Akkermansia muciniphila
Well tolerated in trials; controlled use lasts only about seven months, and long-term daily use is untestedLarazotide
Gray-market products carry contamination, mislabeling and mis-dosing risks- How it is obtained
Akkermansia muciniphila
Over the counter as a dietary supplementLarazotide
Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals
| Akkermansia muciniphila | Larazotide | |
|---|---|---|
| FDA status / approved use | Sold as a dietary supplement with no FDA approval; pasteurized form authorized as an EU Novel Food | Investigational and not FDA-approved; pivotal Phase 3 trial halted in 2022 |
| Marketed for | Gut barrier integrity, metabolic syndrome, insulin sensitivity | Leaky gut, celiac disease |
| Outcome areas | Gut health; Blood sugar / insulin sensitivity | Gut health |
| Evidence grade | Clinical data | Clinical data |
| How it works | Mucus-dwelling gut bacterium; a heat-stable surface protein improves the gut barrier | Zonulin antagonist designed to tighten the junctions between intestinal cells |
| Route and dosing | Oral capsule, taken daily | Oral capsule swallowed before meals |
| Headline human result | Regained 1.2 kg vs 3.2 kg on placebo after dieting in a 90-person 2026 RCT; a 142-person 2026 trial missed its primary endpoint | Phase 3 CeDLara trial stopped in 2022 after interim analysis showed it would miss its symptom endpoint |
| Strongest evidence | Depommier 2019 proof-of-concept RCT, Nat MedAkkermansia muciniphila evidence reviewPubMed 31263284 | Leffler, Gastroenterology 2015Larazotide evidence reviewPubMed 25683116 |
| Key safety signal | Well tolerated in trials; controlled use lasts only about seven months, and long-term daily use is untested | Gray-market products carry contamination, mislabeling and mis-dosing risks |
| How it is obtained | Over the counter as a dietary supplement | Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Akkermansia has real, if mixed, positive human RCT data — the founding trial showed metabolic improvements from the pasteurized strain, though a larger follow-up missed its primary endpoint. Larazotide's real Phase 2 celiac signal never converted into a Phase 3 win. Different targets entirely: Akkermansia targets the mucin layer and metabolic markers, larazotide targets the tight junctions themselves.
Akkermansia muciniphila fits if
Metabolic markers under a gut-barrier framing are the target, and you're buying the pasteurized form the trials actually used.
Larazotide fits if
Celiac-specific tight-junction regulation is the specific interest, understanding the pivotal trial for that exact use failed.
Akkermansia muciniphila vs Larazotide: common questions
- Is either Akkermansia or larazotide FDA-approved?
- No. Akkermansia is sold as a dietary supplement with no FDA approval; pasteurized form authorized as an EU Novel Food. Larazotide is investigational and not FDA-approved; pivotal Phase 3 trial halted in 2022.
- Which has stronger human evidence, Akkermansia or larazotide?
- Neither clearly. Both have human clinical data. The key source for Akkermansia is Depommier 2019 proof-of-concept RCT, Nat Med; for larazotide, it is Leffler, Gastroenterology 2015.
- What are the main safety concerns with Akkermansia and larazotide?
- Akkermansia is well tolerated in trials; controlled use lasts only about seven months, and long-term daily use is untested. With larazotide, gray-market products carry contamination, mislabeling and mis-dosing risks.
Key studies behind each
Akkermansia muciniphila
- Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L, MICRO-Obes Consortium, Dumas ME, Rizkalla SW, Doré J, Cani PD, Clément K. (2016). Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. PubMed 26100928
- Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. (2013). Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. PubMed 23671105
- Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD. (2017). A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. PubMed 27892954
- Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. (2019). Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. PubMed 31263284
Larazotide
- Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. (2007). The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. PubMed 17697209
- Fasano A. (2011). Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. PubMed 21248165
- Kelly CP, Green PH, Murray JA, et al. (2013). Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther. PubMed 23163616
- Leffler DA, Kelly CP, Green PH, et al. (2015). Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. PubMed 25683116
The full evidence reviews
- Akkermansia muciniphila: what the human evidence actually shows
A gut bacterium with a well-designed 32-person pilot behind it — and, as of 2026, two larger follow-ups that split the verdict.
Updated August 2026
- Larazotide: the leaky-gut peptide that failed its Phase 3 trial
An 8-amino-acid tight-junction regulator with real celiac data and a failed pivotal trial — and why the supplement use runs far ahead of the evidence.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Larazotide availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: Arc-1Ark HealthARSYNL RxAscend VitalityAVARA RxAVArx